Similar activation models can strengthen trial recruitment, precision medicine, and population health by converting data into ...

Pharmaceutical Commerce's conversation with Vikram Anand, president of compliance services at EVERSANA, on pharmacovigilance (PV) infrastructure closes with a look at what connect ...

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on ...

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing ...

Episode 1 of Supply Chain Signal breaks down the FDA's PreCheck pilot, the US Section 301 probe into German drug pricing, and CMS's move to make Medicare drug price negotiation permanent. The debut ...

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after ...

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster benefits verification, prior authorization initiation, affordability support, ...

The API Innovation Center's Gerren McHam on China's new supply chain rules, reshoring policy, and where US drug manufacturing goes next. For decades, America's reliance on China for the ingredients ...

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap. In part 1 of a 3-part interview ...

Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models.

Cardinal Health's Michelle Britt discusses the operating costs, cash flow strain and reimbursement pressures facing ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.